Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HitGenSHSE:688222 +0.35%90 Days Payable is 62.44 as of Mar. 2026, which is 19% below its 10-year median of 77.52. GuruFocus rates SHSE:688222 with a GF Score™ of 90/100 and a GF Value™ of ¥26.07 (Fairly Valued). The stock has 1 warning sign investors should review. Among 702 Biotechnology companies, HitGen ranks worse than 69.66% on this metric.
HitGen's average Accounts Payable for the
three
months ended in Mar. 2026 was ¥48.0 Mil. HitGen's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ¥70.1 Mil.
Hence, HitGen's Days Payable for the
three
months ended in Mar. 2026 was 62.44.
The historical rank and industry rank for HitGen's Days Payable or its related term are showing as below:
SHSE:688222'
s Days Payable Range Over the Past 10 Years
Min: 26.06 Med: 77.52 Max: 253.48
Current: 47.26
During the past 10 years, HitGen's highest Days Payable was 253.48. The lowest was 26.06. And the median was 77.52.
SHSE:688222's Days Payable is ranked worse than 69.66% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs SHSE:688222: 47.26
HitGen's Days Payable
increased
from Mar. 2025 (37.98) to Mar. 2026 (62.44).
It may suggest that HitGendelayed paying its suppliers.
HitGen Days Payable Related Terms
HitGen Days Payable Historical Data
* Premium members only.
The historical data trend for HitGen's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688222 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, HitGen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HitGen Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HitGen's Days Payable distribution charts can be found below:
* The bar in red indicates where HitGen's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
HitGen's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HitGen (SHSE:688222) has a Days Payable of 62.44 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HitGen and its competitors. This is 19% below median its historical median of 77.52. Over the past decade, HitGen's Days Payable has ranged from 26.06 to 253.48. According to the industry distribution chart, HitGen ranks #489 out of 702 companies in the Biotechnology industry, placing it in the top 69.7%.
Is HitGen's Days Payable too high?
HitGen's current Days Payable of 62.44 is 19% below median its 10-year median of 77.52. Over the past 10 years, this metric has ranged from a low of 26.06 to a high of 253.48. The Biotechnology industry median Days Payable is 113.10. HitGen's value of 62.44 is 44.8% below this industry median. Based on the distribution chart, HitGen ranks #489 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HitGen has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HitGen's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HitGen ranks #489 out of 702 companies for Days Payable. This places HitGen in the lower half of its industry. The industry median Days Payable is 113.10. HitGen's value of 62.44 is 44.8% below this benchmark. Historically, HitGen's own Days Payable has ranged from 26.06 to 253.48 over the past decade. While the company's 10-year median is 77.52 vs. the industry median of 113.10, HitGen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HitGen's current Days Payable of 62.44 is 44.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HitGen and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HitGen's current Days Payable is 62.44, which is 19% below median its own 10-year median of 77.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HitGen stock overvalued right now?
Based on GuruFocus' analysis, HitGen (SHSE:688222) is currently considered Fairly Valued. The stock's GF Value™ is ¥26.07, compared to a current price of ¥28.30 — trading 8.6% above its estimated fair value. The current Days Payable is 62.44, which is 19% below median its 10-year median of 77.52 and 44.8% below the Biotechnology industry median of 113.10. HitGen's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For HitGen (SHSE:688222), the current Days Payable is 62.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HitGen (SHSE:688222) Overvalued in 2026?
Based on GuruFocus' analysis, HitGen stock appears to be overvalued.
The current stock price of ¥28.30 is trading 8.6% above its estimated GF Value™ of ¥26.07.
GuruFocus considers HitGen to be Fairly Valued.
Key valuation signals for SHSE:688222:
Days Payable: 62.44 (19% below median its 10-year median of 77.52)
GF Value™: ¥26.07 vs. price of ¥28.30 (8.6% above fair value)
Industry Position: 44.8% below the Biotechnology median (#489 of 702)
No single metric tells the full story. See the SHSE:688222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health and quality of life. It provides therapeutic solutions to address unmet medical needs. Centered on its internationally DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics. The group has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutic molecules and tool molecules to the world-wide pharmaceutical industry.
90GF Score
Get the complete analysis for SHSE:688222
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688222 has been successfully added to your 
